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Although an increasing number of studies have been conducted to evaluate the association
between human papillomavirus (HPV) infections and distribution of HPV types worldwide with
the risk of prostate cancer (PC), the results remain inadequate. Hence, we investigated the associ-
ation between HPV infection and PC risk using a meta-analysis. Relevant studies from January
1990 to December 2016 were searched in PubMed, Web of sciences, and Scopus databases.
Pooled odds ratio (OR) and their corresponding 95% confidence interval (CI) were calculated
to find the association between the prevalence of HPV and prostate cancer risk. To do so, data
from 24 studies with 5546 prostate cancer cases were pooled in order to evaluate the hetero-
geneity of chief parameters including study region, specimen type, HPV DNA source, detection
technique, publication calendar period, andGleason score. All statistical analyseswere performed
using STATA 11 andMedCalc 13. A significant positive associationwas found betweenHPV infec-
tion and PC risk (OR = 1.281; P = 0.026). The genotype 16 was more frequently found in patients
with PC which significantly increased the cancer risk (OR = 1.60; P < 0.001). Age 65 and older
could significantly escalate PC risk (OR= 3.564; P< 0.001). Our results clearly favor the potential
pathogenetic link between HPV infection and increased risk of PC affirming that HPV infections
could play a part in the risk of PC.
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1 INTRODUCTION
Prostate cancer (PC) is the second prevalent cancer in men
worldwide.1 Not much evidence exists on the development of PC
and the precise mechanisms involved in this process. Certain aspects
might affect a man's risk of getting PC including age >50 years, eth-
nicity, acquired/inherited genetic mutations, and sexually transmitted
infections (STIs).2,3 Previous studies have shown that HPV could be
among the STD culprits’ involved in PC.
HPV is a small epitheliotropic, non-enveloped, double-stranded
DNA virus that belongs to Papillomaviridae family.4–6 Having over
150 fully sequenced types, one-third of HPV types infect the genital
tract.7,8 Zur Husaen discovered the participation of HPV infection in
cancer in 1977.9,10 Later in 1990, McNicol and Dodd first identified
HPV DNA in prostatic tissues using polymerase chain reaction assay
(PCR).11 Further investigations revealed that viral infections could
affect PC development by activating the chronic inflammatory pro-
cesses leading to DNA damage and cancer.12–14 Above and beyond
(moreover, on the other hand, etc.), the E6/E7 oncoproteins of HPV
types 16 and 18 have been described to eternize prostate epithe-
lial cells.15 Surprisingly, several epidemiological and biological studies
have displayed the presence of HPV in both healthy and cancerous
prostate tissues.15,16 Therefore, the associationbetween thePCdevel-
opment andHPV infections is still controversial.
Because the validity of these contrary views is not clear, we under-
took this study and intended to investigate any possible association
betweenHPV infection and prostate cancer risk using ameta-analysis.
2 MATERIALS AND METHODS
2.1 Study selection
In this meta-analysis, relevant previous studies from January 1990
to December 2016 were searched in PubMed, Web of sciences and
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Scopus databases. These searcheswere performed using the following
keywords: “Papillomavirus/HPV,” “Risk factor,” “Human” and “Prostate
cancer OR prostate tumor” with “OR” and “AND” and “NOT” Boolean
operators in the Title/Abstract/Keywords fields. Also, we screened
citations manually in retrieved articles to identify additional eligible
studies. Literature published in English and human population studies
were included in the current meta-analysis.
2.2 Inclusion and exclusion criteria
Inclusion criteria were:1 publication time between 1990 and 2016,2
detection of HPV DNA in biopsy tissues,3 detection of antibodies in
serological studies,4 case–control studies.
The subsequent studies were ruled out:
(i) Studies on immunosuppressive patients
(ii) Congress abstracts, case report articles, and review articles
(iii) Investigations published in languages other than English
(iv) Studies with no extractable data
(v) Meta-analysis or systematic reviews and duplicate publication
of the same survey (or published both in English and other lan-
guages). The exception was duplicate studied in which sample
sizes and detailed results were provided.
2.3 Data extraction and quality assessment
The obtained information from each study consisted of the follow-
ing items: first author, year of publication, the location of study, sam-
ple sizes, specimens’ type (tissue or serum), sources of controls, HPV
detection method, HPV genotype, the age of patients and Gleason
score of prostate cancer. The Newcastle–Ottawa Scale was used for
assessing the methodological quality. Studies were graded as low,
moderate or high-quality according to the scores of 0–3, 4–6 and
7–9, respectively. Two independent investigators without knowledge
of existing scores examined the selected studies based on the criteria
described above to resolve any discrepancies.
2.4 Statistical methods
We used pooled ORs and their corresponding 95% confidence inter-
vals (CIs) to evaluate the association of HPV infection and prostate
cancer risk. Cochran's Q test was used to assess heterogeneity and
the I2 index was employed for calculating the variation in the pooled
estimations. For the latter analysis, significance was considered at
P < 0.05.17,18 The meta-analysis was performed with a random-
effects model when the heterogeneity of the individual studies was
statistically significant. Otherwise, a fixed-effects model was used.
Meanwhile, a sensitivity analysis was done by consecutively eliminat-
ing a particular study or group of them (if any) with maximum impact
on the heterogeneity test. A funnel plot was established for checking
the existence of publication bias and symmetric assumption. The
funnel plot asymmetry was measured by Egger's linear regression test
and Begg's test (P< 0.05was considered representative of statistically
significant publicationbias).19 Subgroup analysiswas performedbased
on the year of publication, age of the patients, biological sample, HPV
detection method, HPV genotype and studied Continents by using the
available individual data. All statistical analyses were conducted using
statistical software (STATA; version 11.0; Stata Corporation, College
Station, TX, USA) andMedCalc version 13.
3 RESULTS
3.1 Characteristics of the included studies
The assortment process shown in Figure 1 was designed according to
Preferred Reporting Items for Systematic Reviews andMeta-Analyses
(PRISMA) guidelines.20 Based on the exclusion/inclusion criteria, 24
case–control studies were included in the final meta-analysis among
which 13 and 11 had reported HPV prevalence in tissue and serum,
respectively. These studies included 5576 cases and 7946 healthy sub-
jects. Among 24 case–control studies, 13were carried out in American
people, six were done in European people, threewere fromAsians, one
from Africans and one study was done in Oceania people. Publication
year of these studieswas ranged from1992 to2016.More information
on the studies is shown in Table 1.
3.2 Main results of this meta-analysis
According to Table 2, a significant positive association was found
between HPV infection and prostate cancer risk. The pooled odds
ratio (OR) was 1.281 (95% CI, 1.030–1.594; P = 0.026) for the asso-
ciation between HPV infection and occurrence of prostate cancer
(Figure 2). According to the subgroup analysis, the genotype 16 was
more frequently found in patients with prostate cancer and signifi-
cantly increased the cancer risk (OR = 1.60; 95% CI, 1.231–2.081;
P < 0.001). Age > 65 years old significantly increased prostate can-
cer risk (OR = 3.564; 95% CI, 1.806–6.962; P < 0.001) and the dom-
inant detection method was PCR (OR = 2.794; 95% CI, 1.432–5.453;
P = 0.003). Based on the studies in Oceania and Asia, the associa-
tion between HPV infection and prostate cancer risk was the highest
(OR = 21; 95% CI, 1.777–248.1; P = 0.016) and (OR = 14.697; 95%
CI, 2.787–77.50; P = 0.002), respectively. For the studies in Europe,
the association between HPV infection and prostate cancer risk was
the lowest (OR= 1.095; 95%CI, 0.912–1.313; P= 0.331). The associa-
tion between HPV infection and prostate cancer was more frequently
found in a biological tissue sample (OR = 3.622; 95% CI, 2.197–5.971;
P < 0.001). According to Lowess smoothing analysis, the OR for the
association between HPV infection and risk of PC was decreased over
time until 2003while increased afterwards (Figure 3).
3.3 Sensitivity analysis
A sensitivity analysis was performed by sequential omission of individ-
ual and groups of studies. The pooled OR did not significantly deviate
from the consecutive exclusion of any participants or group of studies,
indicating that our results were statistically robust (Figure 4).
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F IGURE 1 Flow-chart of the selected studies
3.4 Heterogeneity and publication bias
The heterogeneity analysis was conducted using Cochran's Q test and
the I2 index. Significance for the heterogeneity results was consid-
ered with an I2 > 50% and P-value heterogeneity <0.05. Heterogene-
ity between studies was observed (I2 = 61.23%; P < 0.001; Table 2 &
Figure 5). Publication bias was examined by a funnel plot and Egger's
and Begg's tests. In most cases, significant publication bias was identi-
fied (Table 2).
4 DISCUSSION
There are several factors with clear/less clear effect on PC risk such as
the age (>50), geographical region, mutations in some cellular genes,
inflammation and infectious agents.12,21 Several previous studies, both
epidemiological and biological, have proposed some infectious agents
asmajor causes of cancers worldwide.22 Viral infections are important
risk factors involved in initiation and development of approximately
18–20% of cancers.23
Few meta-analyses have investigated the correlation between the
risk of prostate cancer and HPV infections.15 In a study in 2005, HPV
infection, found either in sera or tissue, was shown to be a risk factor
of prostate cancer (OR = 1.39; 95% CI, 1.12–2.06).24 In other studies,
the most common oncogenic virus types (HPV 16 and/or HPV 18)
were evaluated and it was claimed that “the overall risk of prostate
cancer was not significantly increased by either HPV 16 (OR = 1.09;
95% CI, 0.97–1.23) or HPV 18 (OR = 1.05; 95% CI, 0.89–1.24) infec-
tions in sera and tissue combined while it was significantly increased
when HPV DNA was detected in prostate tissues.”2,25 In the newest
meta-analysis, HPV infection of each type was significantly associ-
ated with an increased risk of prostate cancer (OR = 1.32; 95% CI,
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F IGURE 2 Forest plot displaying the association betweenHPV infection and risk of prostate cancer [Colour figure can be viewed at
wileyonlinelibrary.com]
F IGURE 3 The odds ratio of HPV infection with prostate cancer
over time of publication [Colour figure can be viewed at
wileyonlinelibrary.com]
1.12–1.55). Also, they demonstrated that “the statistically significant
association was absent for studies performed on sera (OR= 1.03; 95%
CI, 0.95–1.12) while persisted in studies on tissues (OR = 1.79; 95%
CI, 1.29–2.49).”15 In this study, we found a significant positive associ-
ation between HPV infection and prostate cancer risk. The pooled OR
was 1.281 (95% CI, 1.030–1.594; P = 0.026). According to the hetero-
geneity assessing results, the divergence of HPV infection occurrence
globally indicates the impact of demographic aspects like geographical
area, ethnicity, and lifestyle on the prevalence of HPV infection in PC.
Viruses could elevate cancer risk through cellular transformation,
interrupting the cell-cycle control, amplifying cell turnover rates, and
immune suppression.26 One of the most important of these aspects
is chronic inflammation.27 Previous studies have been shown chronic
inflammation related to viral infection is involved in different cancers
such as thyroid, breast, and prostate cancer.12,28
So far, a linkage has been described between HPV and various
malignancies that involve the anogenital tract and those involving
the head and neck cancers. The two possible ways introduced HPV
employs to participate in PC, immortalization, and inflammation.29
The persistent infection of HPV and the association with tumor
development was approved in some cancers such as cervical can-
cer and head and neck cancers.30,31 Although, HPV infection can be
cleared by the immune system in the majority of individuals, but in
some cases theHPV infection can become to persist infection. Patients
with persistent HPV infection is high risk for acquiring abnormalities
for some reasons such as chronic inflammation and reasonsmentioned
earlier.32
Its prevalencewas14% forPCand27% for nodular hyperplasia; and
HPV-18was theonly type identified13 whereas the significantly preva-
lent genotype of the 24 case–control studies was HPV16 which can
exacerbate the cancer risk (P< 0.001). Several studies confirm the cur-
rent result.15 Themost frequently detected high-risk HPVs in prostate
cancers are types 16, 18, 31, 33, and 58,25 which is consistent with our
results. A prior study has also described high-risk-HPV type 16 posi-
tivity in 53.8% of malignant and in 20.0% of benign prostate biopsies.
Low-risk HPV types such as HPV6 and HPV11 presented in benign
controls in a higher proportion suggesting the formation of benign
and precancerous lesions in prostate cancer.33 There could be sev-
eral hypotheses addressing this difference, prevalence and genotypes
distribution of HPV, including geographical, sample size, sampling and
methodological differences.
The PC is less frequent in Asia, Africa, Central and South America
than North America, northwestern Europe and Australia. It occurs
more frequent in African-American men and less regular in Asian-
American and Hispanic/Latino men than in non-Hispanic whites.
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F IGURE 4 A sensitivity analysis plot for
single studies on the summary effect size
F IGURE 5 Begg's funnel plot with pseudo 95%CL for publication
bias of the association between human papillomavirus infection and
PC risk [Colour figure can be viewed at wileyonlinelibrary.com]
Previous meta-analysis studies have been shown that a high HPV
prevalence in Africa whereas a low prevalence in Europe and North
America in cervical cancer.34 In this study, the most studies were con-
ducted in America [13/24 (86%)] but the risk of HPV in PC was shown
to be higher in Asia and Oceana. High-risk HPVs have been identified
in PCs in North/South America, Europe, Asia and Pacific region.
More importantly, studies demonstrated up to 22.3% of men with a
preliminary negative prostate biopsy, develop PCwithin 11 years.35,36
Hence, follow-up the presence of the pathogenic agent in benign
tissues before the development of the disease is amissing step ofmany
published researches to comprise further HPV role in PC develop-
ment. Yang et al. demonstrated that the prevalence of HPVwas higher
(OR=1.29; 95%CI, 1.03–1.63) in studies publishedduring 2000–2015
(19.43%; 95% CI, 18.25–20.65%) than those in 1990–1999 (15.74%;
95% CI, 13.06–18.73%), whereas we showed the prevalence of HPV
was (OR = 1.38; 95% CI, 1.13–1.69) in studies published before 2004
(P < 0.001). This issue could be due to the development of hygienic
habits and methods of transmission of genital infections. Also, accord-
ing to Lowess smoothing analysis, the OR for the association between
HPV infection and risk of PC decreased over time until 2003, but after
that, it increased again (Figure 3). Another aspect about the prevalence
of HPV increasing is due to detection protocols improvement.15
Professional European/American guidelines and recommendations
for PC screening initiate with measuring prostate-specific antigen
(PSA) elevations, prostate cancer antigen 3 gene (PCA3) evalua-
tion and digital rectal examination (DRE) for nodules, induration or
asymmetry.37,38 Should the results come back abnormal, patients
would be referred to a urologist for a prostate biopsy.39 Biopsy spec-
imens are subjected to up-to-date molecular tests to determine the
aggressiveness of prostate cancer better. There are tests based on
cell proliferation consist of immunohistochemistry (IHC) evaluation of
Ki-67, and the cell-cycle progression (CCP) score measured by quanti-
tative reverse transcription polymerase chain reaction (RT-PCR). The
results provide valuable information that could affect the extent of
therapy.40,41 Also, there are tests on the basis of molecular charac-
teristics including PTEN tumor suppressor loss on chromosome 10q
assessment, prostate cancer classifier (Decipher), Cancer gene panel
(Oncotype DX prostate), and Proteomic biomarkers. This category of
detection methods will determine markers specific to prostate can-
cer prognosis.41–44 Furthermore, there are molecular basis methods
that detect pathogens such as HPV that contributes to the PC. Here,
the dominant detection method of subjected studies was PCR which
is parallel with the results of the previously mentioned meta-analysis.
Advancements in molecular biology resulted in threemajor categories
to detect HPVs in PC patients. HPV DNA testing is the first approach
developed for routine clinical testing. One of the important factors in
the sensitivity of PCR is using L1 primer, because when use L1 primer
forHPVdetecting often L1 gene is lost duringHPV integration into the
host genome, and that it causesmany of positive sampleswas reported
as negative sample.45
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The second approach, HPV RNA testing, looks for expression of E6
andE7RNA,wouldprovideequivalent sensitivity andbetter specificity
than HPV DNA testing. The third approach is cellular marker detec-
tion, which diagnoses HPV-associated disease.46 It is notable that in
the PCR-basedmethods, type-specific primers could bemore sensitive
to distinguish 200 bp smaller HPVDNA sequences.47
The link was prominent in studies with HPV detected in tissues.
Furthermore, we revealed the geographic variations in the associa-
tion strengths and emphasized other methodological parameters (e.g.,
detection method) in further analyses that have never been shown
in the previous studies. Previous studies have been shown that HPV
infection is associatedwithprostate cancer, but a comprehensive study
should be conducted that has the following characteristics: study of
the type-specific prevalence of HPV infections based on region, age
of patients, diagnostic methods, type of sample and year of study.
This informative information could be provided a comprehensive map
data for possible vaccine. For this purpose, we done this meta-analysis
and analyzed the relationship between HPV infections and the risk of
prostate cancer.
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